Over the past two decades, many companies have tried and failed to develop safe and effective interventions for gastroesophageal reflux disease to the point where the field was practically unfinanceable. But EndoGastric Solutions has not only survived the journey, it’s also gained FDA approval, reimbursement codes, and is now scaling up to serve a large patient population that previously had no good therapeutic options. Its recent $45 million venture capital round solidifies its lead.
Kenneth Chang, MD, a thought-leader in the field of gastrointestinal endoscopy, speaks about the migration of surgery to less invasive procedures that is changing gastroenterology as it has so many other clinical specialties. Innovations here promise to increase the numbers of patients who get treated for some difficult conditions.